Clinical Trial Update: Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics and pharmacodynamics study evaluating BI 1356 in subjects with varying degrees of liver impairment compared with healthy subjects to as…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Disease

Drugs mentioned

• BI 1356 (BI 1356)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hepatic Insufficiency | Phase 1 | Status: COMPLETED